ArticleFrontiers in endocrinology2025
Association between the TyGBS index and all-cause and cardiovascular mortality in diabetic stroke patients.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Stroke patients with diabetes face elevated mortality risks, posing a global public health challenge. The TyG (Triglyceride-Glucose) index and Oxidative Balance Score (OBS) are potential predictors of mortality, but their combined impact remains unclear. This study explores the association between Triglyceride-Glucose to Oxidative Balance Score Ratio (TyGBS) and all-cause and cardiovascular mortality in diabetic stroke patients. Methods: Data from 556 diabetic stroke patients in the NHANES 1999-2018 cohort were analyzed. Mortality outcomes were determined using the National Death Index. TyGBS, calculated as the TyG index divided by OBS, was assessed for its association with mortality through Kaplan-Meier analysis, multivariable Cox regression, restricted cubic splines (RCS), and subgroup analyses. Results: Over a mean follow-up of 73 months, 210 (49.4%) patients died, including 65 (15.3%) from cardiovascular causes. Higher TyGBS levels were significantly associated with increased mortality risks. Kaplan-Meier analysis showed the lowest mortality in the lowest TyGBS quartile (Q1) and the highest in Q4 (log-rank p<0.001). Cox regression revealed that each unit increase in TyGBS raised all-cause mortality risk by 360% (HR 4.60, 95% CI 3.21-6.59) and cardiovascular mortality risk by 357% (HR 4.57, 95% CI 2.43-8.60). The RCS analysis indicated a nonlinear association, showing a significant increase in mortality risk when TyGBS was less than 1.163 (p for nonlinearity = 0.002). Conclusion: TyGBS, a novel ratio integrating metabolic and oxidative pathways, demonstrates a critical clinical threshold for prioritizing interventions in diabetic stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.